Rhinoplasty vs Filler: Which Nose Job Is Right?

What Each Can and Cannot Change

코 필러 대 코 성형 (ko pilleo dae ko seonghyeong — nose filler vs nose surgery) is a decision defined by one hard limit: filler adds volume; it cannot remove tissue, reposition cartilage, or alter bone. Surgical rhinoplasty operates on structure — bone, cartilage, and the soft tissue envelope — and its results do not reverse.

The table below maps eleven common nose-reshaping goals to each option. “Yes” means the technique can reliably achieve the goal. “No” means it cannot, regardless of injector skill or surgical expertise.

Two points in the table warrant emphasis.

Hump camouflage is not hump reduction. Filler placed above and below a dorsal hump elevates the bridge on both sides, making the hump proportionally less prominent in profile — an optical illusion. The cartilage and bone of the hump remain unchanged. Rhinoplasty removes the hump by surgically reducing the dorsal cartilage and/or bone (osteotomy — surgical cutting of nasal bone to narrow or straighten the bridge).

Reversibility applies only to hyaluronic acid (HA) filler. Permanent fillers — Radiesse (calcium hydroxylapatite) and Sculptra (poly-L-lactic acid) — cannot be dissolved once injected. Experienced Korean injectors generally avoid permanent fillers in the nose precisely because vascular complications cannot be rapidly reversed with an enzyme injection. If you are considering filler, confirm the product is HA-based before proceeding.

Korean Society of Plastic and Reconstructive Surgeons (KSPRS; 대한성형외과학회, Daehan Seonghyeong Oegwa Haghoe — South Korea’s official professional and certification board for plastic surgeons) board certification requires six years of medical school, a four-year plastic surgery residency, and passage of KSPRS board examinations.¹ Confirming that a surgeon performing rhinoplasty holds this credential is verifiable directly through the KSPRS public registry.²

Filler Risks: Vascular Occlusion Is Serious

The nose has a dense, terminal arterial supply. The dorsum and tip are fed primarily by terminal branches of the facial artery and the ophthalmic artery system — vessels with few collateral connections. When an injector delivers filler into or immediately adjacent to one of these vessels, two injury mechanisms are possible:

Compression occlusion: Filler volume presses externally on a vessel wall, restricting blood flow. Tissue downstream becomes ischaemic (oxygen-deprived) within minutes to hours.

Intravascular injection: Filler enters the vessel lumen directly. In the nose, the ophthalmic artery connection means filler can travel retrogradely toward the retinal artery — the vessel that supplies the eye. Retinal artery occlusion causes sudden, permanent vision loss.

The consequence of untreated vascular occlusion progresses in stages: blanching of the skin, pain, then grey-purple discolouration as tissue dies, and finally full-thickness skin necrosis (tissue death requiring wound care or surgical reconstruction). The window for effective treatment is narrow — typically two to six hours.

Treatment protocol when occlusion is suspected:

• Immediate injection of hyaluronidase (the enzyme that dissolves HA filler) into the affected area and along the estimated vessel path
• High-dose hyaluronidase — not a conservative amount
• Aspirin (antiplatelet) and warm compress to encourage vasodilation
• Emergency ophthalmology referral if any visual symptoms appear

This is why the single most important question to ask before nose filler is: “Do you have hyaluronidase on-site, and what is your occlusion protocol?” An injector who cannot answer both parts clearly represents a procedural risk that is independent of their technical skill.

Permanent fillers in the nose carry the same vascular risk during injection — with the critical difference that hyaluronidase cannot dissolve them if occlusion occurs. This is not a theoretical concern; it is the primary reason permanent nasal filler is outside standard practice among experienced Korean aesthetic medicine practitioners.

Surgical rhinoplasty does not carry vascular occlusion risk because no injectable material is introduced into nasal vessels. It carries its own distinct risk profile — general anaesthesia, infection, asymmetry, revision rates — but vascular occlusion is not among them.

Who Should Choose Surgery vs Filler

Neither option is universally superior. The right choice depends on the specific goal, the patient’s timeline, and their tolerance for the respective risk profiles.

Filler is appropriate when:

• The goal is camouflage of a single mild feature — specifically, a dorsal hump that reads as prominent in profile but does not require structural correction
• The patient is not ready for surgery (recovery time, general anaesthesia, cost) and wants a reversible first step
• The goal is to preview a bridge height change before committing to a permanent implant or cartilage graft in surgery
• The change needed is minor and additive — adding bridge height in a patient with a flat dorsum, for example

Surgery is appropriate when:

• The goal involves any form of reduction — hump removal, tip deprojection (reducing how far the tip protrudes), nostril narrowing, or bridge narrowing
• Tip refinement is the primary goal — filler cannot reshape cartilage
• There is a functional component: deviated septum, nasal valve collapse, or chronic obstruction
• The patient wants a permanent result and does not want to return for repeat sessions every 6–18 months
• The patient has had repeated filler and wants a lasting solution — noting that prior filler creates scar tissue that the surgeon will need to account for

One practical use case for filler that experienced Korean surgeons sometimes recommend: a single HA filler session to simulate the bridge height a surgical implant would achieve, allowing the patient to assess the proportional result in real life before committing to rhinoplasty. This “trial” approach only applies to bridge height — it cannot simulate tip work or hump removal.

Cost and Longevity Comparison

All prices in KRW, USD, and AUD. FX rates as of July 2026 (approximate): 1 USD ≈ ₩1,370; 1 AUD ≈ ₩890.

The cost crossover point — where accumulated filler sessions exceed the one-time surgical fee — occurs between five and ten sessions for most patients. A patient who begins nose filler at age 25 and continues through age 35 at three sessions over ten years crosses into surgical-cost territory at the lower end of the filler price range.

The compounding factor that the table cannot fully capture is the scar tissue cost. Repeated HA filler injections stimulate collagen deposition and fibrotic tissue in the nasal soft tissue envelope. A rhinoplasty surgeon operating on a nose with a significant filler history faces thicker, less pliable tissue — which limits the definition achievable and may require additional operative time. Some Korean surgeons charge a higher fee for rhinoplasty cases with prior filler history precisely because of this complexity.

Korean surgical fees are significantly lower than equivalent procedures in Western markets (where rhinoplasty fees in Australia and the United States commonly range from $8,000–20,000 AUD and $7,000–15,000 USD respectively), but the directional logic — that repeated filler sessions approach surgery cost over time while adding procedural complexity — holds regardless of geography.

Sources

¹ KSPRS board certification training requirements — Korean Society of Plastic and Reconstructive Surgeons, Board Certification Registry. https://www.plasticsurgery.or.kr/

² KSPRS public surgeon verification registry — Korean Society of Plastic and Reconstructive Surgeons, Board Certification Registry. https://www.plasticsurgery.or.kr/